$List of International \ Collaborative \ Research \ Projects \ Approved \ by \ HMSC \\ during \ meetings \ held \ on \ 26^{th} \& \ 27^{th} May, \ 2022 \ (through \ VC)$

1.	Genome-Wide Association Study in a Aplastic Anemia	n Indian Cohort of Pa	tients with Acquired
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. Rishi Dhawan	American Society of H USA	Iematology (ASH),
	Assistant Professor All India Institute of Medical Sciences	Date ofapproval	May 26, 2022
	(AIIMS), New Delhi-110029, Delhi	Total budget	Rs. 1,12,76,247
		Duration	44 Months
		Subject area	Haematology
	Approved. However, the PI must sul clearance of AIIMS, New Delhi to ICM		
2.	Angiographic Outflow Assessment: Pe	diatric to Adult-Onset G	Blaucomas
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr.Shikha Gupta	ARVO Foundation for	Eye Research, USA
	Assistant Professor All India Institute of Medical Sciences	Date of approval	May 26, 2022
	(AIIMS), New Delhi-110029, Delhi	Total budget	Rs. 7,50,000
		Duration	12 Months
		Subject area	Ophthalmology
	Approved. However, the Committee study participants is advisable since a n		

3.	Comparison of blood group antigen backgrounds	profiles for donors f	from different ethnic
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. Swati Sanjay Kulkarni	Australian Red Cross	Lifeblood, Australia
	Scientist D ICMR- National Institute of	Date of approval	May 26, 2022
	Immunohaematology (NIIH), Mumbai-400012, Maharashtra	Total budget	Nil
		Duration	12 Months
		Subject area	Genomics
4.	submitted by PI before initiation of the Development of a non-invasive diagnot LF Sensor		Filariasis detection –
	Principal Investigator	Funding/Collaboration	ng Agency
	Prof. Sadhana Sharma	Bill & Melinda Gates USA	Foundation (BMGF),
	Professor & Head All India Institute of Medical Sciences	Date of approval	May 26, 2022
	(AIIMS), Patna-801507, Bihar	Total budget	Rs. 74,93,500
		Duration	12 Months
		Subject area	Filariasis
	Approved with suggestions.		

	Principal Investigator	Funding/Collaborat	ting Agency
	Prof. Reena Das	Bill & Melinda Gate USA	s Foundation (BMGF),
	Professor Postgraduate Institute of Medical	Date of approval	May 26, 2022
	Education & Research (PGIMER), Chandigarh-160012	Total budget	Rs. 3,84,60,240
		Duration	24 Months
		Subject area	Nutrition
	Approved.		
6.	Strengthening Health Economics Evid	lence for India	
	Principal Investigator	Funding/Collaborat	ting Agency
	Dr. Shankar Prinja	Bill & Melinda Gate USA	s Foundation (BMGF),
	Additional Professor Postgraduate Institute of Medical	Date of approval	May 26, 2022
	Education & Research (PGIMER), Chandigarh-160012	Total budget	Rs. 39,06,600
		Duration	21 Months
		Subject area	Public Health
	Approved with suggestions.	I	

7.	Implementation Research on Efficacy of	f Pill-in-Hand Adheren	ce Monitoring
	Principal Investigator	Funding/Collaborat	ing Agency
	Prof. Sarang Deo	Bill & Melinda Gates USA	Foundation (BMGF),
	Professor Indian School of Business,	Date of approval	May 26, 2022
	Hyderabad-500111, Telangana	Total budget	Rs. 6,38,64,866
		Duration	18 Months
		Subject area	Tuberculosis
	Approved with certain conditions.		
8.	The Clinical Value of Ultrasound by procedures	ased Navigation update	te in cranial resection
	Principal Investigator	Funding/Collaborat	ing Agency
	Prof. Aliasgar V Moiyadi	Brainlab AG, German	ny
	Professor and Chief Tata Memorial Centre (TMC),	Date of approval	May 26, 2022
	Mumbai – 400012, Maharashtra	Total budget	Rs. 33,25,000
		Duration	24 Months
		Subject area	Neurosurgery
	Approved.		

Principal Investigator	Funding/Collabora	ting Agency
Dr. VivekanandJha	Cambridge University Foundation Trust and Cambridge, United I	d the University of
Executive Director George Institute for Global Health, India	Date of approval	May 26, 2022
maia	Total budget	Rs. 2,95,44,750
	Duration	18 Months
	Subject area	Infectious Disease
Approved. The Committee endorsed Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE– II)	nunity and hospitals wit	
Antimicrobial resistance in a commextended-spectrum cephalosporin,	nunity and hospitals wit	stin resistance amo
Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE–II)	nunity and hospitals wit carbapenem and colis Funding/Collaborar	ting Agency
Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE– II) Principal Investigator Dr. CP Girish Kumar Scientist E ICMR-National Institute of	runity and hospitals with carbapenem and colision of the carbapenem and carbapenem	ting Agency Control and Prevention
Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE– II) Principal Investigator Dr. CP Girish Kumar Scientist E	runity and hospitals with carbapenem and colision of the carbapenem and	ting Agency Control and Preventic
Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE– II) Principal Investigator Dr. CP Girish Kumar Scientist E ICMR-National Institute of Epidemiology(NIE),	runity and hospitals with carbapenem and colision of the carbapenem and carbapenem	ting Agency Control and Prevention May 26, 2022
Antimicrobial resistance in a commextended-spectrum cephalosporin, Enterobacteriaceae (PHASE– II) Principal Investigator Dr. CP Girish Kumar Scientist E ICMR-National Institute of Epidemiology(NIE),	runity and hospitals with carbapenem and colision of the carbapenem and carbapenem	ting Agency Control and Prevention May 26, 2022 Rs. 1,50,12,000

11.	Capacity Building and Strengthening of Prevent Antimicrobial Resistance in Industrial	-	Control to Detect and
	Principal Investigator	Funding/Collaborati	ng Agency
	Prof. Purva Mathur	Centers for Disease Co (CDC), USA	ontrol and Prevention
	Professor All India Institute of Medical Sciences	Date of approval	May 26, 2022
	(AIIMS), New Delhi-110029, Delhi	Total budget	Rs. 37,37,50,000
		Duration	60 Months
		Subject area	Capacity Building
12.	Approved for 17 sites out of 21 sites. (AIIMS, Jodhpur; P.D Hinduja Natio Mumbai; Tata Medical Center, Kol Varanasi) should be submitted to ICMI Second Harmonic Generation Measurer Corneas	nal Hospital and Med lkata and Homi Bhat R before initiation of the	ical Research Centre, bha Cancer Hospital, e study.
	Principal Investigator	Funding/Collaborati	ng Agency
	Dr. Sunita Chaurasia	Consejo Superior de I Científicas, Spain	nvestigaciones
	Consultant LV Prasad Eye Institute,	Date of approval	May 26, 2022
	Hyderabad-500034,Telangana	Total budget	Rs. 5,20,000
		Duration	24 Months
		Subject area	Ophthalmology
	Approved.However, a valid IEC clear Institute, Hyderabad should be submi study.		

	Principal Investigator	Funding/Collaborat	ting Agency
	Dr. Falguni Pati	Deutsche Forschungs Germany	sgemeinschaft (DFG)
	Associate Professor Indian Institute of Technology Hyderabad (IITH), Sangareddy,	Date of approval	May 26, 2022
	Kandi-502285, Telangana	Total budget	Rs. 59,32,696
		Duration	36 Months
		Subject area	Life Sciences
14.	Approved. However, the MoU between should be submitted by the PI to ICM. Validation of the Pediatric Autoimment children with autoimmune encephalitis	R before initiation of th	e study.
14.	should be submitted by the PI to ICM Validation of the Pediatric Autoimm	R before initiation of th	erity Score (PASS)
14.	Should be submitted by the PI to ICM Validation of the Pediatric Autoimm children with autoimmune encephalitis	R before initiation of the	erity Score (PASS) ting Agency
14.	Should be submitted by the PI to ICM Validation of the Pediatric Autoimm children with autoimmune encephalitis Principal Investigator Prof. Naveen Sankyan Professor	R before initiation of the nune Encephalitis Several Funding/Collaborate	erity Score (PASS) ting Agency
14.	Validation of the Pediatric Autoimmedildren with autoimmune encephalitis Principal Investigator Prof. Naveen Sankyan	R before initiation of the nune Encephalitis Seven Funding/Collaborate Encephalitis Society.	erity Score (PASS) ting Agency , UK
14.	Validation of the Pediatric Autoimmehildren with autoimmune encephalitis Principal Investigator Prof. Naveen Sankyan Professor Postgraduate Institute of Medical Education & Research (PGIMER),	R before initiation of the nune Encephalitis Seven Funding/Collaborate Encephalitis Society. Date of approval	erity Score (PASS) ting Agency , UK May 26, 2022
14.	Validation of the Pediatric Autoimmehildren with autoimmune encephalitis Principal Investigator Prof. Naveen Sankyan Professor Postgraduate Institute of Medical Education & Research (PGIMER),	Funding/Collaborate Encephalitis Society. Date of approval Total budget	erity Score (PASS) ting Agency , UK May 26, 2022 Rs. 10,10,897

15.	Prioritizing hypertension control and car	e by strengthening pri	mary nearm care
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Pankaj Bhardwaj	Global Health Advoc	eacy Incubator, USA
	Additional Professor All India Institute of Medical Sciences	Date of approval	May 26, 2022
	(AIIMS), Jodhpur-342005, Rajasthan	Total budget	Rs. 54,75,000
		Duration	12 Months
		Subject area	Public Health
16.	Approved. However, the IEC clearance from State authorities to conduct the before initiation of the study. Designing a scalable solution for	study should be sub-	mitted by PI to ICM
16.	from State authorities to conduct the before initiation of the study. Designing a scalable solution for tuberculosis (MDR-TB) care in Pune, In	study should be sub-	in multidrug-resista
16.	from State authorities to conduct the before initiation of the study. Designing a scalable solution for	study should be sub-	in multidrug-resista
16.	from State authorities to conduct the before initiation of the study. Designing a scalable solution for tuberculosis (MDR-TB) care in Pune, In Principal Investigator	minimizing delays dia Funding/Collaborat	in multidrug-resistating Agency nool, USA May 26, 2022 Rs. 10,00,000
16.	from State authorities to conduct the before initiation of the study. Designing a scalable solution for tuberculosis (MDR-TB) care in Pune, In Principal Investigator Dr. Sachin Ramchandra Atre Research Coordinator Dr. D Y Patil Medical College Hospital and Research Centre,	minimizing delays dia Funding/Collaborat Harvard Medical Sch Date of approval Total budget	in multidrug-resistating Agency nool, USA May 26, 2022 Rs. 10,00,000

	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Amrita Prajwal Rao	ICMR-IAVI Joint Ca Initiated Research (II	_
	Scientist D ICMR-National AIDS Research	Date of approval	May 26, 2022
	Institute (NARI), Pune-411026, Maharashtra	Total budget	Rs. 25,74,750
		Duration	12 Months
		Subject area	HIV/AIDS/STD
18.	Approved. The Committee endorsed the The Food Environment Toolbox: The Environments, in Low- and Middle-Incomments.	ools to Measure Na	tural and Built Food
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Suparna Ghosh-Jerath	IMMANA Competiti	ve Research Grants
	Professor and Head Public Health Foundation of India,	Date of approval	May 26, 2022
	Gurugram-122002, Haryana	Total budget	Rs. 35,54,453
		Duration	24 Months
		Subject area	Nutrition
	Approved. Committee endorsed the de	l	

	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Samiran Panda	Imperial College Lor	ndon, UK
	Addl. DG and Head (ECD) Indian Council of Medical Research, New Delhi-110029, Delhi	Date of approval Total budget	May 26, 2022 Rs. 2,37,44,000
		Duration Subject area	36 Months Capacity Building
	Approved. The Committee endorsed Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco	l serve as the PI after me report/result/mode	superannuation of D l be shared with Go
20.	Roy, Sc E/ECD Division, ICMR wil	l serve as the PI after me report/result/mode ublic health managers	superannuation of D l be shared with Go for local level planning
20.	Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco Ministries/Depts. & policy makers, print disease prevention & control. Treatment Optimisation for blood President American President Pres	l serve as the PI after me report/result/mode ublic health managers	superannuation of D l be shared with Go for local level plannin combinations in Ind
20.	Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco Ministries/Depts. & policy makers, print disease prevention & control. Treatment Optimisation for blood Pre (TOPSPIN)	l serve as the PI after me report/result/mode ublic health managers : essure with Single-Pill	superannuation of D l be shared with Go for local level planning combinations in Ind
20.	Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco Ministries/Depts. & policy makers, principal in disease prevention & control. Treatment Optimisation for blood Pre (TOPSPIN) Principal Investigator Prof. Dorairaj Prabhakaran Executive Director Centre for Chronic Disease Control	I serve as the PI after ome report/result/mode ublic health managers assure with Single-Pill Funding/Collaborate	superannuation of D l be shared with Go for local level planning combinations in Ind
20.	Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco Ministries/Depts. & policy makers, principal in disease prevention & control. Treatment Optimisation for blood Pre (TOPSPIN) Principal Investigator Prof. Dorairaj Prabhakaran Executive Director	I serve as the PI after ome report/result/mode ublic health managers assure with Single-Pill Funding/Collaborat Imperial College Lor	superannuation of E l be shared with Go for local level planning combinations in Index cing Agency andon, UK
20.	Roy, Sc E/ECD Division, ICMR will Samiran Panda. The periodic outco Ministries/Depts. & policy makers, principal in disease prevention & control. Treatment Optimisation for blood Pre (TOPSPIN) Principal Investigator Prof. Dorairaj Prabhakaran Executive Director Centre for Chronic Disease Control	I serve as the PI after time report/result/mode ablic health managers is sure with Single-Pill Funding/Collaborat Imperial College Lor Date of approval	superannuation of E l be shared with Go for local level planning combinations in Index cing Agency andon, UK

21. Covid-19 vaccine access program in Inc	lia	
Principal Investigator	Funding/Collaborat	ing Agency
Dr. Samiran Panda	International AIDS V (IAVI), USA	accine Initiative
Addl. DG and Head (ECD) Indian Council of Medical Research,	Date of approval	May 26, 2022
New Delhi-110029, Delhi	Total budget	Nil
	Duration	18 Months
	Subject area	Public Health
Approved. The Committee endorsed th	e decision.	
22. Maternal-Child Health and Infectious D	isease (MCH-ID) Scho	olar Training Program
Principal Investigator	Funding/Collaborat	ing Agency
Dr. Shanta Dutta	Johns Hopkins Unive	ersity, USA
Director and Scientist G ICMR-National Institute of Cholera	Date of approval	May 26, 2022
and Enteric Diseases (NICED), Kolkata-700010, West Bengal	Total budget	Rs. 29,99,500
	Duration	18 Months
	Subject area	Infectious Diseases
Approved. However, Institutional Ethi submitted by the PI to ICMR before in		ee of NICED should be
		_

Dr. Jeyashree K Scientist D ICMR-National Institute of Epidemiology(NIE), Chennai-600 077, Tamil Nadu D Approved subject to submission of the du PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalize	•	mg, USA May 26, 2022 Rs. 1,70,21,968 12 Months Tuberculosis
Scientist D ICMR-National Institute of Epidemiology(NIE), Chennai-600 077, Tamil Nadu D Solution Approved subject to submission of the depl. However, the comments from Central followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalization	Oate of approval Cotal budget Ouration Subject area uly signed Data Sharin	May 26, 2022 Rs. 1,70,21,968 12 Months Tuberculosis
ICMR-National Institute of Epidemiology(NIE), Chennai-600 077, Tamil Nadu D Approved subject to submission of the du PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding is Elimination Programme among Marginalize	Cotal budget Ouration Subject area uly signed Data Sharin	Rs. 1,70,21,968 12 Months Tuberculosis
Approved subject to submission of the du PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalization.	Ouration Subject area uly signed Data Sharin	12 Months Tuberculosis
Approved subject to submission of the du PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalization.	ubject area uly signed Data Sharir	Tuberculosis
Approved subject to submission of the du PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalization	uly signed Data Sharir	
PI. However, the comments from Centra followed by the PI. 24. Evaluation of Active Case Finding in Elimination Programme among Marginalized	•	ng Agreement by the
	implemented by Na eed and Vulnerable Po	tional Tuberculosis pulations of India
Principal Investigator F	'unding/Collaborating	g Agency
Dr. Hemant Deepak Shewade JS	SI Research and Train	ng, USA
Scientist E ICMR-National Institute of	Date of approval	May 26, 2022
Epidemiology(NIE), Chennai-600 077, Tamil Nadu	otal budget	Rs. 1,78,05,040
D	Ouration	18 Months
S	ubject area	Tuberculosis
Approved subject to submission of the foreign funding agency to ICMR before in		ent between PI and

25.	Prospective Urban-Rural Epidemiology rural differences in risk factors of cardi chronic disease outcomes, including Co India Study	iovascular respiratory,	neurological and othe
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Prem Kumar Mony	Mc Master University	y, Canada
	Professor & Head St John's Research Institute	Date of approval	May 26, 2022
	Koramangala, Bangalore-560034, Karnataka	Total budget	Rs. 2,72,89,639
		Duration	60 Months
		Subject area	Cardiovascular Diseases
	Approved with suggestions.		
26.	Optimising Informed CONsent in clinic feasibility of an adapted QuinteT Recruit		_
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Nithya Gogtay	Medical Research Co National Institute of I (NIHR), UK	` /
	Professor & Head Seth G.S Medical College and K.E.M	Date of approval	May 26, 2022
	Hospital, Mumbai-400012, Maharashtra	Total budget	Rs. 7,82,000
		Duration	12 Months
		Subject area	Bioethics
	Approved with suggestions.	<u> </u>	

27.	Transcriptomics of nephrotic syndron lymphocytes	ne: RNA sequencing	g of peripheral blood
	Principal Investigator	Funding/Collaborat	ing Agency
	Prof. Arvind Bagga	Medical Research Co	uncil (MRC), UK
	All India Institute of Medical Sciences	Date of approval	May 26, 2022
		Total budget	Rs. 4,50,000
		Duration	12 Months
		Subject area	Nephrology
	Approved.		
28.	The Mega randomized Registry Tr OXygenation targets (Mega-ROX)	rial Comparing Cons	servative vs. Liberal
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Kishore Mangal	Medical Research Ins New Zealand	stitute of New Zealand,
	Senior Consultant Eternal Multispeciality Hospital,	Date of approval	May 26, 2022
	Jaipur-302017, Rajasthan	Total budget	Rs. 3,40,000
		Duration	36 Months
		Subject area	Respiratory Health
	Approved.		

29.	Building Non-Communicable Eye Disease Research Capacity in India		
	Principal Investigator	Funding/Collaboration	ng Agency
	Mr. Thulasiraj Ravilla	National Institutes of I	Health (NIH), USA
	Executive Director Aravind Eye Hospital, Anna Nagar	Date of approval	May 26, 2022
	Madurai-625020, Tamilnadu	Total budget	Rs.1,41,07,470
		Duration	60 Months
		Subject area	Capacity Building
30.	Approved. However, valid/renewed FO Post Graduate Institute of Ophthalmo before initiation of the study. Heart Failure with Reduced Ejection	logy, Madurai be subm	nitted by PI to ICMR
30.	Implementation Strategy	Traction Torypin in	mula. A Late Stage
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. Mohanan Padinhare	National Institutes of I	Health (NIH), USA
	Head & President Centre for Chronic Disease Control	Date of approval	May 26, 2022
	(CCDC), New Delhi-110016, Delhi	Total budget	Rs. 12,50,000
		Duration	24 Months
		Subject area	Cardiovascular Diseases
	Approved.		

	Assessing the 5-Year Effects of a 500-day Liquefied Petroleum Gas Cooking Intervention: Continued Follow up of Participants from the Household Air Pollution Intervention Network (HAPIN) trial		
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Kalpana Balakrishnan	National Institutes of	Health (NIH), USA
	Professor and Director Sri Ramachandra Institute of Higher	Date of approval	May 26, 2022
	Education and Research, Chennai-600116, Tamil Nadu	Total budget	Rs. 7,08,75,000
		Duration	05 Months
		Subject area	Environmental Health
	Approved.		
32.	Prenatal Fine Particulate Matter (PM2 (PAHS) Exposures And Their Associate		-
		Funding/Collaborating Agency	
	Principal Investigator	Funding/Collaborat	ing Agency
	Principal Investigator Dr. Naveen Puttaswamy	Funding/Collaborat National Institutes of	• •
	Dr. Naveen Puttaswamy Assistant Professor		• •
	Dr. Naveen Puttaswamy	National Institutes of	Health (NIH), USA
	Dr. Naveen Puttaswamy Assistant Professor Sri Ramachandra Institute of Higher Education and Research,	National Institutes of Date of approval	Health (NIH), USA May 26, 2022
	Dr. Naveen Puttaswamy Assistant Professor Sri Ramachandra Institute of Higher Education and Research,	National Institutes of Date of approval Total budget	May 26, 2022 Rs. 1,83,09,524

33.	Seasonal Conjunctivitis Outbreak Report (SCORPIO)	rting for Prevention and	I Improved Outcomes
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. Lalitha Prajna	National Institutes of I	Health (NIH), USA
	Chief-Microbiologist Aravind Eye Hospital & Post graduate Institute of Ophthalmology, Madurai – 625020, Tamil Nadu	Date of approval	May 26, 2022
		Total budget	Rs. 11,00,000
		Duration	60 Months
		Subject area	Ophthalmology
34.	Approved. Harmonized Diagnostic Assessment of Study of India (LASI)	f Dementia (DAD) for	· Longitudinal Aging
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. Sharmistha Dey	National Institutes of I	Health (NIH), USA
	Additional Professor All India Institute of Medical Sciences	Date of approval	May 26, 2022
	(AIIMS), New Delhi-110029, Delhi	Total budget	Rs. 16,40,00,000
		Duration	54 Months
		Subject area	Geriatrics
	Approved.		

35.	HIV, Gestational Diabetes, and Tubercu	losis in Pregnancy (PraGaTHi)
	Principal Investigator	Funding/Collabo	rating Agency
	Prof Dr. Sanjaykumar Tambe Ganpatrao Tambe	National Institutes	of Health (NIH), USA
	Professor & Head B. J. Government Medical College,	Date of approval	May 26, 2022
	Pune-411001, Maharashtra	Total budget	Rs. 5,76,39,534
		Duration	60 Months
		Subject area	Gestational diabetes, HIV and TB
	Approved. However, the comments of the PI.	NACO are to be in	corporated & followed by
36.	To study the colonization of oral micro its role in the disease progression	biota in the gut of l	HIV-infected subjects and
	Principal Investigator	Funding/Collabo	rating Agency
	Dr. Urvinder Kaur S	National Institutes	of Health (NIH), USA
	NPGH Fogarty Fellow Jawaharlal Nehru University(JNU),	Date of approval	May 26, 2022
	New Delhi-110067, Delhi	Total budget	Rs. 18,68,512
		Duration	12 Months
		Subject area	HIV/AIDS/ STD
	Approved. However, the comments of NACO are to be incorporated & followed by the PI.		

37.	Adapting an effective intervention for eneeds of key populations in India	enhancing engagement	in HIV care to meet the
	Principal Investigator	Funding/Collaborat	ing Agency
	Ms. Shruta Amit Rawat	National Institutes of	Health (NIH), USA
	Research Manager The Humsafar Trust,	Date of approval	May 26, 2022
	Mumbai-400055, Maharashtra	Total budget	Rs. 1,77,39,000
		Duration	36 Months
		Subject area	HIV/AIDS/ STD
38.	Approved. However, the comments of the PI. Comparative analysis of the in-vitro of fibronectin assay-derived chondroprogly human articular cartilage using surfaced	hondrogenic potential genitors from non-dise	between migratory and
	Principal Investigator	Funding/Collaborat	ing Agency
	Dr. Elizabeth Vinod	National Research, E Innovation Office, H	-
	Associate Professor Christian Medical College (CMC),	Date of approval	May 26, 2022
	Vellore-632004, Tamil Nadu	Total budget	D = 7.10.000
	, , , , , , , , , , , , , , , , , , , ,	Total buuget	Rs. 7,10,000
	, 613.0 00200 ,, 141121 1 ,4400	Duration Duration	24 Months
	, 613.0 00200 , 14111111 , 1400		

39.	An Investigator Initiated, International Multi-centre, Multi-Arm, Multi-Stage Randomised Double Blind Placebo Controlled Trial of Angiotensin Receptor Blocker (ARB) & Chemokine Receptor Type 2 (CCR2) Antagonist for the treatment of COVID-19 (CLARITY 2.0)		
	Principal Investigator	Funding/Collaboration	ng Agency
	Dr. VivekanandJha	NHMRC Clinical Tria of Sydney, Australia	ls Centre, University
	Executive Director George Institute for Global Health,	Date of approval	May 26, 2022
	India	Total budget	Rs. 1,22,00,000
		Duration	18 Months
		Subject area	Infectious Diseases
40.	Mobile Mosquitoes - understanding the mosquitoes in India, Mexico, Tanzania a Principal Investigator		
	Dr. Ashwani Kumar	Novo Nordisk Founda Caixa Foundation, Spa UK and Volkswagen S	nin Wellcome Trust,
			rintung, Germany
	Scientist G & Director ICMR-Vector Control Research	Date of approval	May 26, 2022
	Scientist G & Director ICMR-Vector Control Research Centre (VCRC), Pudducherry-605006		•
	ICMR-Vector Control Research	Date of approval	May 26, 2022
	ICMR-Vector Control Research	Date of approval Total budget	May 26, 2022 Rs. 2,53,56,010

1 41 · I	Burden of Pneumococcal Disease among under five children and elderly population in Punjab Chandigarh and Haryana, India: Retrospective Surveillance Data Analysis		
Principal Investigator	Funding/Collaborat	ing Agency	
Prof. Madhu Gupta	Pfizer Inc., USA		
Professor Postgraduate Institute of Medical	Date of approval	May 26, 2022	
Education & Research (PGIMER), Chandigarh-160012	Total budget	Rs.29,46,930	
	Duration	12 Months	
	Subject area	Public Health	
Approved. The Institutional Ethics Coshould be submitted to ICMR before in 42. Study of Antimicrobial Prescription Patrand Reserve) Classification	nitiation of the study.		
Principal Investigator	Funding/Collaborat	ing Agency	
Dr. Uday Venkat Mateti	Royal Society of Tro Hygiene (RSTMH), U		
Asst. Professor	Date of approval	May 26, 2022	
Institute of Pharmaceutical Sciences,		•	
Institute of Pharmaceutical Sciences, Nitte (Deemed to be University), Mangaluru-575016, Karnataka	Total budget	Rs. 2,64,999	
Nitte (Deemed to be University),	Total budget Duration	Rs. 2,64,999 12 Months	
Nitte (Deemed to be University),			

43. A randomized controlled trial of Acetar schizophrenia	A randomized controlled trial of Acetazolamide for patients with treatment resistant schizophrenia		
Principal Investigator	Funding/Collaborati	ng Agency	
Dr. Smita N Deshpande	Stanley Medical Resea	arch Institute, USA	
Professor St. Johns Medical College and	Date of approval	May 26, 2022	
Hospital, Bangalore-560034, Karnataka	Total budget	Rs. 40,56,800	
	Duration	36 Months	
	Subject area	Psychiatry	
Approved. However, the IEC clearand should be submitted by PI to ICMR best 44. Epidemiological impact and intersect pandemics in Brazil, Russia, India and St.	fore initiation of the studtion of the COVID-	dy.	
Principal Investigator	Funding/Collaborati	ng Agency	
Prof. Urvashi B. Singh	Stellenbosch University Federal University of Novosibirsk Ministry Russian Federation	Rio de Janeiro, Brazil;	
Professor All India Institute of Medical Sciences	Date of approval	May 26, 2022	
(AIIMS), New Delhi-110029, Delhi	Total budget	Rs. 1,71,49,452 (DST funded)	
	Duration	24 Months	
	Subject area	Infectious Diseases	
Approved only for AIIMS, New Delhi	centre.		

Principal Investigator	Funding/Collabora	ting Agency
Prof. Manju Raj Purohit	The Foundation for l Diagnostics (FIND),	
Professor & Head Ruxmaniben Deepchand Gardi	Date of approval	May 26, 2022
Medical College, Ujjain-456001, Madhya Pradesh	Total budget	Rs. 72,64,590
	Duration	24 Months
Approved with suggestions. Development of a universal real tin (e-PROM) for clinical use and its scenarios		
Development of a universal real tin (e-PROM) for clinical use and its	me, electronic patient repo	rted outcome "motion in multiple c
Development of a universal real ting (e-PROM) for clinical use and its scenarios	me, electronic patient reposystems testing and valida	rted outcome "motion in multiple coting Agency
Development of a universal real tin (e-PROM) for clinical use and its scenarios Principal Investigator	Funding/Collaborate The International Dig Research Collaborate Switzerland Date of approval	rted outcome "motion in multiple continuation time definition of the continuation of t
Development of a universal real tin (e-PROM) for clinical use and its scenarios Principal Investigator Dr. Balu Krishna Sasidharan Professor	Funding/Collaborate The International Dig Research Collaborate Switzerland Date of approval	rted outcome "motion in multiple coting Agency
Development of a universal real ting (e-PROM) for clinical use and its scenarios Principal Investigator Dr. Balu Krishna Sasidharan Professor Christian Medical College (CMC)	Funding/Collaborate The International Digesearch Collaborate Switzerland Date of approval	rted outcome "motion in multiple continuation time definition of the continuation of t

1 4/.	new and pre-existing immunosuppression: a retrospective, observational, multisite, multinational cohort study			
Principal Investigator	Funding/Collaborat	ing Agency		
Prof. George M Varghese	The University of Qu	eensland, Australia		
Professor & Head Christian Medical College (CMC),	Date of approval	May 26, 2022		
Vellore-632004, Tamil Nadu	Total budget	Rs. 25,30,000		
	Duration	12 Months		
	Subject area	Covid 19		
Approved. 48. The effects of multiply-fortified salt on the micronutrient status of preschool children in Punjab, India				
Principal Investigator	Funding/Collaborat	ing Agency		
Prof. Reena Das	Thrasher Research Fo	and, USA		
Professor Postgraduate Institute of Medical	Date of approval	May 26, 2022		
Education & Research (PGIMER), Chandigarh-160012	Total budget	Rs. 78,55,610		
	Duration	24 Months		
	Subject area	Nutrition		
Approved.	<u> </u>			

49.	Feasibility of using Trueprep extracted I Tuberculosis Elimination Program	DNA for Line Probe Assay testing in National		
	Principal Investigator	Funding/Collaborat	ing Agency	
	Dr. Priya Rajendran	United States Allergy and Infectious Diseases(USAID), USA		
	Scientist C ICMR-National Institute for Research	Date of approval	May 26, 2022	
	in Tuberculosis(NIRT), Chennai-600 031, Tamil Nadu	Total budget	Rs. 88,57,102	
		Duration	09 Months	
		Subject area	Tuberculosis	
	Approved.			
50.	Investigation of the genetic cause of Facioscapulohumeral muscular dystrophy (FSHD) in the Indian population: A pilot study			
	Principal Investigator	Funding/Collaborat	ınding/Collaborating Agency	
	Dr. Vishnu VY	University College, London, UK		
	Associate Professor All India Institute of Medical Sciences (AIIMS), New Delhi-110029, Delhi	Date of approval	May 26, 2022	
		Total budget	Rs. 5,00,000 (by AIIMS)	
		Duration	12 Months	
		Subject area	Neurology	
	Approved with recommendation.			

51.	Systems medicine approach to tackle the problems of early diagnosing and prognost stratification of mycosis fungoides		
	Principal Investigator	Funding/Collaborat	ting Agency
	Dr. Dipankar De Additional Professor Postgraduate Institute of Medical Education & Research (PGIMER), Chandigarh-160012	University Hospital Lausanne, Switzerlan under Indo-Swiss Joint Research Program (ISJRP)	
		Date of approval	May 26, 2022
		Total budget	Rs. 55,26,738 (DBT, India)
		Duration	48 Months
		Subject area	Dermatology
52.	Approved. CovidSurg-3:Impact of Covid-19 Infec	ction on Surgical Outco	mes
52.		ction on Surgical Outcor	mes
52.		Funding/Collaborate	ting Agency
52.	CovidSurg-3:Impact of Covid-19 Infection Principal Investigator		ting Agency
52.	CovidSurg-3:Impact of Covid-19 Infector Principal Investigator Dr. Ritu Jain Professor	Funding/Collaborate	ting Agency
52.	CovidSurg-3:Impact of Covid-19 Infect Principal Investigator Dr. Ritu Jain	Funding/Collaborate University of Birmin	ting Agency gham, UK
552.	CovidSurg-3:Impact of Covid-19 Infector Principal Investigator Dr. Ritu Jain Professor Christian Medical College	Funding/Collaborate University of Birmin Date of approval	ting Agency agham, UK May 26, 2022
52.	CovidSurg-3:Impact of Covid-19 Infector Principal Investigator Dr. Ritu Jain Professor Christian Medical College	Funding/Collaborat University of Birmin Date of approval Total budget	ting Agency Igham, UK May 26, 2022 Nil

53.	Co-Benefits of Largescale Organic Farming on Human Health (BLOOM)			
	Principal Investigator	Funding/Collaborating Agency		
	Dr. Poornima Prabhakaran	University of Edinburgh, UK		
	Additional Professor & Head Public Health Foundation of India,	Date of approval	May 26, 2022	
	Gurugram-122002, Haryana	Total budget	Rs. 3,41,46,800	
		Duration	48 Months	
		Subject area	Public Health	
	Approved.	L		
54.	4. Effects of Lacto-vegetarian and Vegan Diet on the Glycaemic and Metabolite Proin Healthy Asian Indians – Available Study			
	Principal Investigator	Funding/Collaborating Agency University of Reading, UK		
	Mrs. Sudha Vasudevan			
	Senior Scientist & Head Madras Diabetes Research	Date of approval	May 26, 2022	
	Foundation, Chennai-600086, Tamil Nadu	Total budget	Rs. 5,62,252	
		Duration	07 Months	
		Subject area	Nutrition	
	Approved.			

55.	Providing senior technical expertise for implementing the Structured Operational Research and Training Initiative (SORT IT) on antimicrobial resistance in Low- and Middle-Income Countries (2022)				
	Principal Investigator	Funding/Collaborating Agency World Health Organization (WHO), Switzerland			
	Dr. Hemant Deepak Shewade				
	Scientist E ICMR-National Institute of Epidemiology(NIE),	Date of approval	May 26, 2022		
	Chennai-600 077, Tamil Nadu	Total budget	Rs. 28,95,787		
		Duration	12 Months		
		Subject area	Antimicrobial Resistance		
	Approved.				
56.	6. The Aim of the project is to Develop the International Cardiac Rehabilitation Registry(ICRR), a health services registry to establish the quality of cardiac rehabilitation delivery and the effectiveness in terms of patient outcomes, in low resource settings				
	Principal Investigator	Funding/Collaborating Agency			
	Dr. Anjali Pramod Zende	York University, Canada and College of Health Sciences, Qatar			
	Consultant & Head Sir H. N. Reliance Foundation	Date of approval	May 26, 2022		
	Hospital and Research Centre, Mumbai-400004, Maharashtra	Total budget	Nil		
		Duration	24 Months		
		Subject area	Cardiovascular Diseases/ Diabetes		
	Approved. However, a copy of the duly signed MOU/Data sharing agreement should be submitted to ICMR before initiation of the study.				
<u> </u>					